原发性肺癌是目前最常见的癌症之一,也是全球癌症相关死亡的主要原因。人表皮生长因子受体2 (HER2)作为一种与非小细胞肺癌预后密切相关的靶点,已成为近年来的研究热点。其中抗体耦联药物这一种新兴的肿瘤治疗手段,作为一类选择性的递送细胞毒物到肿瘤细胞的治疗化合物,为HER2突变型NSCLC的治疗带来了新的希望,克服了传统的化疗药物和单克隆抗体治疗的局限性。本篇综述了ADC药物在HER2阳性的非小细胞肺癌治疗领域的最新进展,探讨了其疗效和安全性的潜力,旨在为未来临床治疗过程中提供参考。Primary lung cancer is one of the most common cancers and the leading cause of cancer-related deaths worldwide. Human epidermal growth factor receptor 2 (HER2), as a target closely related to the prognosis of non-small cell lung cancer, has become a hot research topic in recent years. Among them, antibody-drug conjugates (ADCs), an emerging tumor therapy, as a class of therapeutic compounds that selectively deliver cytotoxic agents to tumor cells, have brought new hope for the treatment of HER2-mutant NSCLC, overcoming the limitations of traditional chemotherapeutic agents and monoclonal antibody therapy. In this review, we present the latest advances in the field of ADC drugs in the treatment of HER2-positive NSCLC and discuss their potential in terms of efficacy and safety, aiming to provide a reference for the future clinical treatment process.
